AKT1 and fatty liver disease: There are several signal transduction pathways that have been proposed to improve hepatic steatosis as a result of incretin-based therapy, such as cAMP-PKA signaling, PI3K-PDK1-Akt/PKB signaling, and AMPK signaling [15].